Ascendis Pharma A/S

After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be? Scrip has int

The new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s

The new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan